Skip to main content
. 2016 Apr 25;7(23):34617–34629. doi: 10.18632/oncotarget.8964

Figure 5. FXR agonist GW4064 could reverse CDDP-induced inhibition of SHP expression.

Figure 5

A. Protein levels of SHP, P-STAT3 and STAT3 in GBC-SD and RBE cells transfected with MOCK or SHP plasmid for 72 h. B, C. The mRNA levels of SHP in GBC-SD (B) and RBE (C) cells transfected with control siRNA (NC) or FXR siRNA (siFXR) for 72 h. Columns, mean of three experiments; bars, SD. *P <0.05, siFXR group compared with NC group. D, E. The mRNA level of SHP in GBC-SD (D) and RBE (E) cells treated with CDDP alone, GW4064 alone and CDDP/GW4064 co-treatment for 12 h. Columns, mean of three experiments; bars, SD. #P <0.05, CDDP-alone group compared with control group. *P <0.05, combination treatment group compared with CDDP-alone group. F. The protein level of SHP in GBC-SD and RBE cells that were exposed to CDDP alone, GW4064 alone and CDDP/GW4064 co-treatment for 12 h. G, H. Luciferase reporter assay (RLA) in GBC-SD (G) and RBE (H) cells transfected with the SHP promoter reporter 24 h and then treated with CDDP alone, GW4064 alone and CDDP/GW4064 co-treatment for 12h. RLA was shown as mean±SD of three independent experiments. #P <0.05, CDDP-alone group compared with control group. *P <0.05, combination treatment group compared with CDDP-alone group.